These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

319 related articles for article (PubMed ID: 19944972)

  • 21. Combating immunosuppression in glioma.
    Vega EA; Graner MW; Sampson JH
    Future Oncol; 2008 Jun; 4(3):433-42. PubMed ID: 18518768
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Systemic inhibition of transforming growth factor-beta in glioma-bearing mice improves the therapeutic efficacy of glioma-associated antigen peptide vaccines.
    Ueda R; Fujita M; Zhu X; Sasaki K; Kastenhuber ER; Kohanbash G; McDonald HA; Harper J; Lonning S; Okada H
    Clin Cancer Res; 2009 Nov; 15(21):6551-9. PubMed ID: 19861464
    [TBL] [Abstract][Full Text] [Related]  

  • 23. FoxP3
    Saleh R; Elkord E
    Cancer Lett; 2020 Oct; 490():174-185. PubMed ID: 32721551
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Dynamics of central and peripheral immunomodulation in a murine glioma model.
    Kennedy BC; Maier LM; D'Amico R; Mandigo CE; Fontana EJ; Waziri A; Assanah MC; Canoll P; Anderson RC; Anderson DE; Bruce JN
    BMC Immunol; 2009 Feb; 10():11. PubMed ID: 19226468
    [TBL] [Abstract][Full Text] [Related]  

  • 25. T cell immunity in patients with malignant glioma: recent progress in dendritic cell-based immunotherapeutic approaches.
    Akasaki Y; Black KL; Yu JS
    Front Biosci; 2005 Sep; 10():2908-21. PubMed ID: 15970545
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Mechanisms of immune evasion by gliomas.
    Rolle CE; Sengupta S; Lesniak MS
    Adv Exp Med Biol; 2012; 746():53-76. PubMed ID: 22639159
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Monitoring immune responses after glioma vaccine immunotherapy.
    Jian B; Yang I; Parsa AT
    Neurosurg Clin N Am; 2010 Jan; 21(1):195-9. PubMed ID: 19944978
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Principles of immunotherapy.
    Liebelt BD; Finocchiaro G; Heimberger AB
    Handb Clin Neurol; 2016; 134():163-81. PubMed ID: 26948354
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Dendritic cell immunotherapy for malignant gliomas.
    Luptrawan A; Liu G; Yu JS
    Rev Recent Clin Trials; 2008 Jan; 3(1):10-21. PubMed ID: 18474011
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Adoptive immunotherapy in patients with recurrent malignant glioma: preliminary results of using autologous whole-tumor vaccine plus granulocyte-macrophage colony-stimulating factor and adoptive transfer of anti-CD3-activated lymphocytes.
    Sloan AE; Dansey R; Zamorano L; Barger G; Hamm C; Diaz F; Baynes R; Wood G
    Neurosurg Focus; 2000 Dec; 9(6):e9. PubMed ID: 16817692
    [TBL] [Abstract][Full Text] [Related]  

  • 31. [The immunosuppressive microenvironment of malignant gliomas].
    Borisov KE; Sakaeva DD
    Arkh Patol; 2015; 77(6):54-63. PubMed ID: 26841651
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Immunological factors relating to the antitumor effect of temozolomide chemoimmunotherapy in a murine glioma model.
    Kim TG; Kim CH; Park JS; Park SD; Kim CK; Chung DS; Hong YK
    Clin Vaccine Immunol; 2010 Jan; 17(1):143-53. PubMed ID: 19889936
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Preferential migration of regulatory T cells mediated by glioma-secreted chemokines can be blocked with chemotherapy.
    Jordan JT; Sun W; Hussain SF; DeAngulo G; Prabhu SS; Heimberger AB
    Cancer Immunol Immunother; 2008 Jan; 57(1):123-31. PubMed ID: 17522861
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Glioma-derived T cell immunoglobulin- and mucin domain-containing molecule-4 (TIM4) contributes to tumor tolerance.
    Xu L; Xiao H; Xu M; Zhou C; Yi L; Liang H
    J Biol Chem; 2011 Oct; 286(42):36694-9. PubMed ID: 21896488
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Dendritic cell-based immunotherapy for malignant gliomas.
    Akasaki Y; Black KL; Yu JS
    Expert Rev Neurother; 2005 Jul; 5(4):497-508. PubMed ID: 16026233
    [TBL] [Abstract][Full Text] [Related]  

  • 36. T-cell immunotherapy for malignant glioma: toward a combined approach.
    Dietrich PY; Dutoit V; Tran Thang NN; Walker PR
    Curr Opin Oncol; 2010 Nov; 22(6):604-10. PubMed ID: 20739889
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Vaccination with irradiated tumor cells pulsed with an adjuvant that stimulates NKT cells is an effective treatment for glioma.
    Hunn MK; Farrand KJ; Broadley KW; Weinkove R; Ferguson P; Miller RJ; Field CS; Petersen T; McConnell MJ; Hermans IF
    Clin Cancer Res; 2012 Dec; 18(23):6446-59. PubMed ID: 23147997
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Immunotherapy for glioma: Current management and future application.
    Xu S; Tang L; Li X; Fan F; Liu Z
    Cancer Lett; 2020 Apr; 476():1-12. PubMed ID: 32044356
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Adoptive immunotherapy for malignant glioma.
    Mitchell DA; Fecci PE; Sampson JH
    Cancer J; 2003; 9(3):157-66. PubMed ID: 12952301
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Immunologic approaches to therapy for brain tumors.
    Paul DB; Kruse CA
    Curr Neurol Neurosci Rep; 2001 May; 1(3):238-44. PubMed ID: 11898524
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 16.